Products
Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-731
Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Alvircept sudotox is a form of recombinant CD4 derived from Pneumonas aeruginosa exotoxin A, or 'PE4, which has a size of 59,187 daltons and is an anti-viral agent.[1]
Alvircept sudotox is a form of recombinant CD4 derived from Psedomonas aeruginosa exotoxin A, or 'PE40’ as an anti-viral agent. Alvircept Sudotox has been used in trials studying the treatment of HIV Infections.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-731-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-731-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-731-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-731-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A |
| INN Name | Alvircept Sudotox |
| Target | HIV-1 gp120 |
| Format | Fusion Protein |
| Derivation | Pseudomonas aeruginosa human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - CD4 (p55, T cell surface antigen T4/Leu-3) - Pseudomonas aeruginosa exotoxin A |
| VD LC | Fusion - CD4 (p55, T cell surface antigen T4/Leu-3) - Pseudomonas aeruginosa exotoxin A |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | National Institute of Allergy and Infectious Diseases (NIAID) (Bethesda USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
Facebook
LinkedIn
Twitter
